ArticleMolecular cancer therapeutics2022

Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.

Peiyin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.